Tentt

Assertio Sells INDOCIN, SPRIX, SYMPAZAN to Cosette for $35M

Announced
HealthcareDivestiture

Deal Overview

Assertio Holdings has entered into an asset purchase agreement with Cosette Pharmaceuticals to sell Assertio’s remaining rights in INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR and the decommercialized OTREXUP. The upfront consideration is $35.0 million in cash.

The agreement also includes potential additional deferred payments. These include future milestone payments up to $32.0 million tied to sales milestones for SYMPAZAN, OTREXUP and INDOCIN, plus SPRIX-related contingent payments: $1.0 million for successful quality approval and batch delivery by May 31, 2026, an 8% share of gross profits from SPRIX from April 8, 2026 through December 31, 2027, and a $2.0 million payment if 2027 calendar-year net sales of SPRIX exceed $7.0 million.

Key Details

Transaction
Cosette Pharmaceuticals acquires Assertio Holdings
Deal Size
$25M – $50M
Reported Value
$35.0 million

Filed under

Source

Read full article on sec.gov

via SEC EDGAR — 8-K · April 14, 2026

Powered by Tentt

Source healthcare deals for your firm

Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.

Book a 30-min intro call

Related Deals

See all Healthcare deals →